Erratum
Open Access
Erratum to: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study
Annals of General Psychiatry20098:15
https://doi.org/10.1186/1744-859X-8-15
© Geitona et al; licensee BioMed Central Ltd. 2009
Received: 17 June 2009
Accepted: 18 June 2009
Published: 18 June 2009
The original article was published in Annals of General Psychiatry 2008 7:16
Abstract
Correction to Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S and Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry 2008, 7:16. This correction reports changes in the values listed for Ziprasidone and Aripiprazole in Table Ten.
Correction
Following the publication of our article [1], it has come to our attention that there was an error with the values listed for Ziprasidone and Aripiprazole in Table Ten. Table Ten should therefore appear as shown in this correction (Table 1).
Table 1
Mean annual number of stable days and cost per patient by pharmaceutical treatment.
Paliperidone ER | Olanzapine | Risperidone | Quetiapine | Ziprasidone | Aripiprazole | |
|---|---|---|---|---|---|---|
Base case: | ||||||
Cost (€) | 7.030 | 7.034 | 7.082 | 8.321 | 7.807 | 7.713 |
Effectiveness | 272.5 | 272.2 | 265.5 | 260.7 | 258.6 | 260.5 |
Incremental cost and effectiveness compared with paliperidone ER: | ||||||
Cost (€) | - | 4 | 52 | 1.291 | 777 | 683 |
Effectiveness | - | -0.3 | -7.0 | -11.8 | -13.9 | -12.0 |
Notes
Authors’ Affiliations
(1)
Department of Economics, University of Thessaly
(2)
Institute for Economic and Industrial Research
(3)
Department of Health Economics, National School of Public Health
(4)
Janssen-Cilag Pharmaceutical SACI
References
- Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry. 2008, 7: 16-10.1186/1744-859X-7-16.PubMed CentralView ArticlePubMedGoogle Scholar
Copyright
© Geitona et al; licensee BioMed Central Ltd. 2009
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
